Company Product Description Indication Status
Diffusion Pharmaceuticals Inc., of Charlottesville, Va. TSC (trans sodium crocetinate) Vitamin A analogue Severe respiratory symptoms and low oxygen levels in COVID-19 patients  FDA will accelerate its review of the company’s clinical development plan under the Coronavirus Treatment Acceleration Program
Diverse Biotech Inc., of Doylestown, Pa. Unnamed therapy Therapeutic using cannabidiol as a core component  Newly diagnosed glioblastoma FDA granted orphan drug designation
Lipocine Inc., of Salt Lake City LPCN-1148 Oral prodrug of bioidentical testosterone Liver cirrhosis  FDA cleared the IND application for phase II proof-of-concept study in adult male cirrhotic patients
Mateon Therapeutics Inc., of Agoura Hills, Calif. CA4P Fosbretabulin; a vascular-disrupting agent Stage IIB-IV melanoma due to genetic mutations that disproportionately affect pediatric patients  FDA granted rare pediatric disease designation 
Organicell Regenerative Medicine Inc., of Miami Organicell Flow Acellular product derived from amniotic fluid Moderate to severe acute respiratory syndrome due to COVID-19 infection FDA approved the IND application

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments